加载中
NASDAQHealthcareBiotechnology
最新数据
US$471.75
−US$5.16 · -1.08%
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
前收盘价
US$471.75
−US$5.16 · -1.08%
盘中时间采用ET。市场数据可能有所延迟。
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
日内区间
当前US$471.75
52周区间
当前US$471.75
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
93
深度低估
情绪
55
多空交织
风险
33
中等风险
动量
60
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
日内区间
当前US$471.75
52周区间
当前US$471.75
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 9.58亿 USD | 1.8亿 USD | — | — | — |
| 销货成本 | 5614.8万 USD | 623.3万 USD | — | — | — |
| 毛利 | 9.02亿 USD | 1.74亿 USD | — | — | — |
| 研究与开发 | 3.89亿 USD | 2.37亿 USD | 2.72亿 USD | 2.45亿 USD | 2.05亿 USD |
| 销售、一般及管理费用 | 8.14亿 USD | 4.35亿 USD | 1.08亿 USD | 4813万 USD | 3731.8万 USD |
| 营业费用 | 12.02亿 USD | 6.72亿 USD | 3.8亿 USD | 2.94亿 USD | 2.42亿 USD |
| 利息收入 | 3736.4万 USD | 4665.4万 USD | 1957.8万 USD | 218.5万 USD | 36.3万 USD |
| 利息支出 | 2230.9万 USD | 1467.1万 USD | 1271.2万 USD | 396.4万 USD | — |
| 折旧和摊销 | 150.6万 USD | 109.6万 USD | 52.7万 USD | 46.7万 USD | 40.5万 USD |
| 营业利润 | −3亿 USD | −4.98亿 USD | −3.8亿 USD | −2.94亿 USD | −2.42亿 USD |
| 净利润 | −2.88亿 USD | −4.66亿 USD | −3.74亿 USD | −2.95亿 USD | −2.42亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$680.38
上涨空间 44.22%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.17亿0.01%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2.29亿0.12%1853亿 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1.32亿0.29%447亿 USD0.05%US$344.74+1.22%
State Street SPDR S&P Biotech ETFXBI1.31亿1.32%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF1.19亿0.12%954亿 USD0.05%US$235+0.80%
First Trust NYSE Arca Biotechnology Index FundFBT7957.9万2.75%28.91亿 USD0.55%US$265.4+2.00%
iShares Biotechnology ETFIBB7953.09万0.76%108.2亿 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA5024.23万0.23%218.24亿 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
